- Broad telaprevir registration program for treatment-naive and <br> treatment-failure HCV patients nears enrollment completion -- Vertex expects to initiate VX-770 registration program in cystic <br> fibrosis -- Vertex ends 2008 with approximately $830 million in cash, cash <br> equivalents & marketable securities -
CAMBRIDGE, Mass., Feb 02, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its 2008 financial results on Monday, February 9, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EST.
CAMBRIDGE, Mass., Feb 05, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated President, CEO, and Founder Joshua Boger, Ph.D. Will Retire in May 2009 Vertex Board Member Matthew Emmens Appointed President and Will Transition to President, CEO and Chairman in May 2009 The board of directors
CAMBRIDGE, Mass., Feb 09, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated : Telaprevir dosing in Phase 3 ADVANCE clinical trial complete and Phase 3 REALIZE clinical trial completes enrollment VX-770 expected to commence registration program for cystic fibrosis in first half of 2009
CAMBRIDGE, Mass., Feb 18, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 9,000,000 shares of its common stock in an underwritten public offering under an automatically effective shelf
<i>- Vertex to acquire privately-held ViroChem Pharma in cash and stock
transaction -</i><i>- Two HCV polymerase inhibitors, VCH-222 and VCH-759, have
demonstrated significant antiviral activity in early clinical trials -</i><i>- First STAT-C combination trial with telaprevir planned for 2H 2009
start -</i>
CAMBRIDGE, Mass., Mar 13, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Cowen & Company 29 th Annual Health Care Conference on Tuesday, March 17, 2009 at 2:25 p.m. EDT.
<i><b>- PROVE 3 SVR results accepted as late-breaker oral presentation -</b></i><i><b>- First clinical results for VCH-222 in HCV patients accepted as
poster presentation -</b></i>
<i><b>- Primary endpoints of safety and tolerability to be evaluated in
Phase 2a clinical trial -</b></i><i><b>- Measurements of CFTR function to be assessed as secondary
endpoints -</b></i><i><b>- Trial to enroll approximately 90 patients with the F508del CFTR
mutation -</b></i>
CAMBRIDGE, Mass., Mar 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at Citi's 4 th Annual Biotech Day on Wednesday, April 1, 2009 at 2:40 p.m. EDT and at the Canaccord Adams Hepatitis C Conference on
CAMBRIDGE, Mass., Apr 03, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its first quarter 2009 financial results on Thursday, April 16, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
<i>- Telaprevir registration program on track; VCH-222 enters
multi-dose, 3-day viral kinetic study -</i><i>- VX-770 will start registration program in CF patients with G551D
mutation -</i><i>-Vertex ends first quarter with $869 million of cash, cash
equivalents and marketable securities-</i>
<i>-PROVE 3 results to be presented at late breaker session on Saturday,
April 25, 2009-</i><i>-Interim data from two Phase 2 studies of telaprevir indicate
activity across multiple genotypes in treatment-naïve HCV patients-</i><i>-Early data from newly-acquired polymerase inhibitors suggest rapid,
powerful antiviral activity with favorable safety and tolerability
profile-</i>
<i>- Superior SVR rates with telaprevir across all HCV genotype 1
non-responders and relapser patients and patients with cirrhosis - up to
76% in prior relapsers -</i><i>- PROVE 3 showed 51% and 52% SVR rates in telaprevir-based regimens
compared to 14% in the 48-week control arm</i><i>-</i><i>- Treatment-failure patient population represents the greatest unmet
medical need in HCV -</i>
<i><b>-Addition of telaprevir to standard HCV therapies significantly
improved rates of sustained viral response in half the time of current
treatments-</b></i><i><b>-SVR rates in Phase 2b studies of up to 69% with 24 weeks of
telaprevir-based treatment-</b></i><i><b>-Phase 3 program ongoing in more than 2,200 patients-</b></i>
CAMBRIDGE, Mass., May 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Dr. Peter Mueller, Vertex's Executive Vice President, Drug Innovation and Realization and Chief Scientific Officer, will expand his leadership responsibilities to cover all of
CAMBRIDGE, Mass., May 06, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Bank of America and Merrill Lynch 2009 Health Care Conference on Tuesday, May 12, 2009 at 8:40 a.m. EDT; at R. W.
CAMBRIDGE, Mass., May 14, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results of the voting at its 2009 Annual Meeting of Stockholders. At the meeting, stockholders approved the amendment to Vertex's Amended and Restated 2006 Stock and Option Plan
<i>-Over 3 million Americans have chronic hepatitis C -</i>
-<i>Baby boomers account for 2 of every 3 cases of hepatitis C virus and
vast majority unaware they have this chronic disease </i>-
-<i>Cost burden of hepatitis C to Medicare projected to increase 500% as
baby boomers with HCV age into severe complications of liver disease-</i>
<i><b>-Registration program to evaluate improvements in lung function
(FEV</b></i><sub><i><b>1</b></i></sub><i><b>), restoration of CFTR
activity and safety-</b></i><i><b>-Program designed to support registration in cystic fibrosis
patients with the G551D mutation and to provide first evaluation of
activity in patients with F508del mutations-</b></i><i><b>-Primary endpoint for patients with G551D mutation is improvement
in FEV</b></i><sub><i><b>1 </b></i></sub><i><b>through 24 weeks-</b></i>
CAMBRIDGE, Mass., Jun 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Goldman Sachs 30 th Annual Global Healthcare Conference. Matt Emmens, Chairman, President and Chief Executive Officer of Vertex, will
CAMBRIDGE, Mass., Jun 08, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $103.3 million in aggregate principal amount of those notes for
CAMBRIDGE, Mass., Jun 23, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the 2009 Piper Jaffray Europe Conference on Tuesday, June 23, 2009 at 4:30 p.m. BST (11:30 a.m. EDT).
CAMBRIDGE, Mass., Jul 07, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that Jeffrey Leiden, M.D., Ph.D. and Dennis Winger joined its board of directors. "Jeff and Dennis add tremendous medical and biomedical business perspective to our board.
CAMBRIDGE, Mass., Jul 27, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its second quarter 2009 financial results on Wednesday, August 5, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
<i>-- Vertex to receive $105 million from Mitsubishi following signing,
plus the potential for additional milestones upon commercialization --</i><i>-- Phase 3 registration program for telaprevir in Japan expected to
complete enrollment in the third quarter of 2009 --</i>
<i>- Telaprevir Phase 3 registration program in hepatitis C on track;
NDA submission anticipated in second half of 2010 -</i><br /><i>- Vertex advancing two drug candidates aimed at the underlying
disease mechanism of the orphan disorder cystic fibrosis -</i><br /><i>- Vertex ends second quarter with $754 million of cash, cash
equivalents and marketable securities; Vertex will add to this position
with $105 million of cash through an amended agreement with Mitsubishi
Tanabe Pharma Corporation -</i><br />
CAMBRIDGE, Mass., Aug 06, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its corporate presentation at the Canaccord Adams Global Growth Conference on Tuesday, August 11, 2009 at 10:30 a.m. EDT.
CAMBRIDGE, Mass., Sep 03, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Thomas Weisel Partners 2009 Healthcare Conference on Wednesday, September 9, 2009 at 2:40 p.m.
CAMBRIDGE, Mass., Sep 18, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the UBS Global Life Sciences Conference on Tuesday, September 22, 2009 at 2:30 p.m. EDT and at the JMP Securities Healthcare Conference on
<i>-More than 800 Vertex employees take part in service activities at
more than 20 nonprofit and community organizations around the globe-</i><br /><i>-Several events focused on promoting students' interest in science-</i><br /><i>-Day of Service held to honor Vertex founder and long-time CEO Joshua
Boger, Ph.D.-</i><br />
<i><b>Presentations to include SVR results from Study C208 exploring
twice-daily telaprevir-based dosing regimen, final PROVE 3 results and
additional sub-analysis of PROVE 1 and PROVE 2 in "difficult-to-cure"
patients</b></i><br />
CAMBRIDGE, Mass., Sep 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will receive $155 million in cash from two financial transactions. In the first transaction, Vertex will receive approximately $120 million in cash for the issuance of notes
<i>-Vertex announces plans to initiate a Phase 2 proof-of-concept trial
for VX-509 in rheumatoid arthritis-</i><br /><i>-Vertex to add $260 million to cash position; company increases
guidance for year-end cash position to approximately $800 million and
adjusts net loss guidance-</i><br /><i>-Vertex announces executive leadership change-</i><br />
CAMBRIDGE, Mass., Oct 14, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will announce its third quarter 2009 financial results on Monday, October 26, 2009 after the financial markets close. The Company will host a conference call at 5:00 p.m. EDT.
<i>-Phase 3 registration programs in hepatitis C and cystic fibrosis on
track-</i><br /><i>-Vertex to present telaprevir SVR data from Study C208 at AASLD
meeting this week-</i><br />
<ul><li class="bwlistitemmarginbottom"><i><b>57% of prior treatment null responder patients achieved an SVR
with a 48-week telaprevir-based regimen</b></i></li><li class="bwlistitemmarginbottom"><i><b>90% of prior treatment relapsers and 55% of prior treatment
partial responders achieved an SVR with 24-week or 48-week
telaprevir-based regimens</b></i></li><li class="bwlistitemmarginbottom"><i><b>Results provide further support for the ongoing Phase 3
registration study, REALIZE, in treatment-failure patients</b></i></li></ul>
CAMBRIDGE, Mass., Oct 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Oppenheimer 20 th Annual Healthcare Conference on Wednesday, November 4, 2009 at 2:10 p.m.
<ul><li class="bwlistitemmarginbottom"><i><b>83% SVR achieved with twice-daily regimen of telaprevir dosed
with PEGASYS and ribavirin</b></i></li><li class="bwlistitemmarginbottom"><i><b>Results highlight the use of response-guided therapy in managing
treatment outcomes</b></i></li><li class="bwlistitemmarginbottom"><i><b>Similar safety and tolerability observed between
telaprevir-based regimens dosed either twice daily or three times daily</b></i></li></ul>
CAMBRIDGE, Mass., Nov 10, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that holders of its 4.75% Convertible Senior Subordinated Notes due 2013 have agreed to exchange approximately $109.0 million in aggregate principal amount of those notes and accrued
CAMBRIDGE, Mass., Nov 12, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentation at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009 at 2:40 p.m. EST.
CAMBRIDGE, Mass., Nov 20, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will webcast its presentations at the Piper Jaffray 21st Annual Health Care Conference on Wednesday, December 2, 2009 at 2:00 p.m.
CAMBRIDGE, Mass., Dec 02, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it intends to offer, subject to market and other conditions, 10,000,000 shares of its common stock in an underwritten public offering under an effective shelf registration
CAMBRIDGE, Mass., Dec 04, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the underwriters of its public offering have exercised in full their option to purchase an additional 1,500,000 shares of common stock at the public offering price of $38.50 per
CAMBRIDGE, Mass., Dec 10, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced the appointment of Nancy J. Wysenski as Executive Vice President and Chief Commercial Officer. Ms. Wysenski has more than 30 years of experience in building commercial operations and